aVb6 pCAR

N/A

Report date: 2025/01/26 18:07:20

Base Information

Drug NameaVb6 pCAR
Drug Alias Nameanti-aV/b6 integrin CAR T-cell therapy (Leucid Bio)anti-alpha-V/beta-6 integrin CAR T-cell therapy (Leucid Bio)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionIntegrin alpha-V/beta-6 modulators
TargetsIntegrin alpha-V/beta-6
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesLeucid Bio Ltd
China Registration ClassN/A

Develop Information

Active CompaniesLeucid Bio Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A